和胃解毒方对食管鳞癌同步放化疗病人血清肿瘤相关因子、免疫因子的影响  

Effect of Hewei Jiedu prescription on serum tumor-related factors and immune factors in patients with concurrent chemoradiotherapy for esophageal squamous cancer

作　　者：林呼[1] 温嘉敏 黄清苑[1] 王晓阳[1] 高博 LIN Hu;WEN Jiamin;HUANG Qingyuan;WANG Xiaoyang;GAO Bo(Department of Traditional Chinese Medicine,Meizhou People′s Hospital,Meizhou Guangdong 514031,China)

机构地区：[1]广东省梅州市人民医院中医科,514031

出　　处：《蚌埠医学院学报》2024年第9期1157-1160,共4页Journal of Bengbu Medical College

基　　金：广东省中医药局科研项目(20191336)。

摘　　要：目的:研究和胃解毒方对食管鳞癌(ESC)同步放化疗(CRT)病人血清肿瘤相关因子、免疫因子及炎性因子的影响。方法:选取ESC同步放化疗病人84例,按照随机数字表法将病人分为观察组和对照组,各42例。对照组行CRT治疗,观察组行CRT联合和胃解毒方治疗。观察2组治疗前后血清细胞角蛋白19片段(CYFRA 21-1)、鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)等肿瘤相关因子水平,血清CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)等TBNK淋巴细胞亚群水平,血清白细胞介素(IL)-6、IL-8、肿瘤坏死因子-α(TNF-α)等炎性因子水平及中医症候积分。结果:治疗后,观察组血清CYFRA 21-1、SCC、CEA水平较对照组低(P<0.01),观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均较对照组高,CD8^(+)水平较对照组低(P<0.01)。观察组血清IL-6、IL-8、TNF-α水平明显较对照组低(P<0.01)。观察组中医症候积分较对照组低(P<0.01);结论:和胃解毒方应用于ESC CRT病人,可有效杀灭ESC细胞,降低肿瘤相关因子水平,改善免疫因子水平。Objective:To study the effect of Hewei Jiedu prescription on serum tumor-related factors,immune factors and inflammatory factors in patients with concurrent chemoradiotherapy(CRT)for esophageal squamous cancer(ESC).Methods:A total of 84 patients with CRT were selected.According to the random number table method,they were divided into observation group and control group,42 cases in each group.The control group was treated with CRT,while the experimental group was treated with CRT and Hewei Jiedu prescription.The level of serum tumor-related factors[cytokeratin 19 fragment(CYFRA 21-1),squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA)],the level of serum TBNK lymphocyte[CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)],the level of serum inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)]and TCM syndrome score of both group were observed before and after treatment.Results:After treatment,the serum levels of CYFRA 21-1,SCC and CEA in the observation group were lower than those in the control group(P<0.01).The levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,while the levels of CD8^(+)were lower than that in the control group(P<0.01).The levels of IL-6,IL-8,TNF-αin the observation group were lower than those in the control group(P<0.01).The TCM syndrome score in the observation group was lower than that in the control group(P<0.01).Conclusions:Hewei Jiedu prescription can effectively kill ESC cells,reduce the level of tumor-related factors and improve the level of immune factors in patients with CRT for ESC.

关 键 词：食管肿瘤 和胃解毒方 同步放化疗 肿瘤相关因子 免疫因子 

分 类 号：R735.1[医药卫生—肿瘤]